• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost.全基因组过表达筛选大肠杆菌对磷霉素的耐药性：MurA 以低适应性成本赋予临床耐药性。
Antimicrob Agents Chemother. 2012 May;56(5):2767-9. doi: 10.1128/AAC.06122-11. Epub 2012 Feb 27.
2
How is fosfomycin resistance developed in Escherichia coli?大肠杆菌中磷霉素耐药性是如何产生的？
Future Microbiol. 2018 Dec;13:1693-1696. doi: 10.2217/fmb-2018-0294. Epub 2018 Dec 11.
3
Identification of a novel UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) from Vibrio fischeri that confers high fosfomycin resistance in Escherichia coli.从费氏弧菌中鉴定出一种新型的尿苷二磷酸-N-乙酰葡糖胺烯醇丙酮酸转移酶（MurA），该酶可使大肠杆菌对磷霉素产生高度抗性。
Arch Microbiol. 2009 May;191(5):425-9. doi: 10.1007/s00203-009-0468-9. Epub 2009 Mar 11.
4
Characterization of fosA5, a new plasmid-mediated fosfomycin resistance gene in Escherichia coli.大肠杆菌中新型质粒介导的磷霉素抗性基因fosA5的特性分析。
Lett Appl Microbiol. 2015 Mar;60(3):259-64. doi: 10.1111/lam.12366. Epub 2014 Dec 21.
5
Identification of a novel fosfomycin-resistant UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) from a soil metagenome.从土壤宏基因组中鉴定一种新型磷霉素耐药 UDP-N-乙酰葡糖胺烯醇式丙酮酸转移酶（MurA）。
Biotechnol Lett. 2013 Feb;35(2):273-8. doi: 10.1007/s10529-012-1074-5. Epub 2012 Nov 10.
6
In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance.肺炎衣原体MurA的体外和体内功能活性，MurA是一种参与肽聚糖合成和磷霉素抗性的UDP-N-乙酰葡糖胺烯醇丙酮酸转移酶。
J Bacteriol. 2003 Feb;185(4):1218-28. doi: 10.1128/JB.185.4.1218-1228.2003.
7
Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.大肠杆菌临床分离株中磷霉素耐药的分子机制。
Int J Antimicrob Agents. 2010 Apr;35(4):333-7. doi: 10.1016/j.ijantimicag.2009.11.011. Epub 2010 Jan 13.
8
Characterization of Fosfomycin Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Human and Pig in Taiwan.台湾地区人和猪源耐磷霉素产超广谱β-内酰胺酶大肠杆菌分离株的特性分析
PLoS One. 2015 Aug 17;10(8):e0135864. doi: 10.1371/journal.pone.0135864. eCollection 2015.
9
Rapid Detection of Fosfomycin Resistance in Escherichia coli.快速检测大肠埃希菌中的磷霉素耐药性。
J Clin Microbiol. 2019 Jan 2;57(1). doi: 10.1128/JCM.01531-18. Print 2019 Jan.
10
Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26.产志贺毒素大肠杆菌O26磷霉素耐药菌株的出现。
Antimicrob Agents Chemother. 1999 Apr;43(4):789-93. doi: 10.1128/AAC.43.4.789.

引用本文的文献

1
Phenotypic and WGS-derived antibiotic resistance patterns of Enteritidis isolates from retail meat and environment during 2014 to 2019 in China.2014年至2019年期间中国零售肉类和环境中肠炎沙门氏菌分离株的表型及全基因组测序衍生的抗生素耐药模式
Front Microbiol. 2025 Jan 27;16:1502138. doi: 10.3389/fmicb.2025.1502138. eCollection 2025.
2
A Targeted Genome-scale Overexpression Platform for Proteobacteria.一种用于变形菌门细菌的靶向基因组规模过表达平台。
bioRxiv. 2024 Mar 4:2024.03.01.582922. doi: 10.1101/2024.03.01.582922.
3
Fosfomycin resistance mechanisms in : an increasing threat.磷霉素耐药机制：日益严峻的威胁。
Front Cell Infect Microbiol. 2023 Jul 4;13:1178547. doi: 10.3389/fcimb.2023.1178547. eCollection 2023.
4
Fosfomycin Resistance in Bacteria Isolated from Companion Animals (Dogs and Cats).从伴侣动物（狗和猫）中分离出的细菌对磷霉素的耐药性
Vet Sci. 2023 May 9;10(5):337. doi: 10.3390/vetsci10050337.
5
The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic.磷霉素引人入胜的生物学与化学特性：唯一上市的膦酸酯类抗生素。
RSC Adv. 2019 Dec 19;9(72):42204-42218. doi: 10.1039/c9ra08299a. eCollection 2019 Dec 18.
6
The Antibiotic Fosfomycin Mimics the Effects of the Intermediate Metabolites Phosphoenolpyruvate and Glyceraldehyde-3-Phosphate on the Transcriptome.抗生素磷霉素通过模拟中间代谢产物磷酸烯醇丙酮酸和 3-磷酸甘油醛的作用来影响转录组。
Int J Mol Sci. 2021 Dec 23;23(1):159. doi: 10.3390/ijms23010159.
7
Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and .铜绿假单胞菌与. 之间磷霉素耐药机制的差异。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0144621. doi: 10.1128/AAC.01446-21. Epub 2021 Nov 22.
8
Selective Culture Medium for Screening of Fosfomycin Resistance in .用于筛选磷霉素耐药性的选择性培养基。
J Clin Microbiol. 2022 Jan 19;60(1):e0206321. doi: 10.1128/JCM.02063-21. Epub 2021 Oct 20.
9
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.用于治疗多重耐药菌引起的新生儿败血症的潜在抗生素
Paediatr Drugs. 2021 Sep;23(5):465-484. doi: 10.1007/s40272-021-00465-z. Epub 2021 Aug 26.
10
QM/MM Study of the Fosfomycin Resistance Mechanism Involving FosB Enzyme.涉及FosB酶的磷霉素耐药机制的量子力学/分子力学研究
ACS Omega. 2021 May 3;6(19):12507-12512. doi: 10.1021/acsomega.1c00096. eCollection 2021 May 18.

本文引用的文献

1
Artificial gene amplification reveals an abundance of promiscuous resistance determinants in Escherichia coli.人工基因扩增揭示了大肠杆菌中大量混杂的耐药决定因素。
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1484-9. doi: 10.1073/pnas.1012108108. Epub 2010 Dec 20.
2
Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.社区中磷霉素使用的增加与产超广谱β-内酰胺酶（ESBL）大肠埃希菌对磷霉素耐药性的平行增加。
J Antimicrob Chemother. 2010 Nov;65(11):2459-63. doi: 10.1093/jac/dkq346. Epub 2010 Sep 16.
3
Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes.日本产 CTX-M 型大肠埃希菌临床分离株中磷霉素耐药的流行情况及新型质粒介导的磷霉素修饰酶的鉴定。
Antimicrob Agents Chemother. 2010 Jul;54(7):3061-4. doi: 10.1128/AAC.01834-09. Epub 2010 Apr 19.
4
Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.大肠杆菌临床分离株中磷霉素耐药的分子机制。
Int J Antimicrob Agents. 2010 Apr;35(4):333-7. doi: 10.1016/j.ijantimicag.2009.11.011. Epub 2010 Jan 13.
5
Fosfomycin: use beyond urinary tract and gastrointestinal infections.磷霉素：在泌尿道和胃肠道感染之外的应用。
Clin Infect Dis. 2008 Apr 1;46(7):1069-77. doi: 10.1086/527442.
6
[Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections].[与尿路感染患者分离出的大肠杆菌中磷霉素耐药性相关的生物学代价]
Rev Esp Quimioter. 2007 Jun;20(2):211-5.
7
Complete set of ORF clones of Escherichia coli ASKA library (a complete set of E. coli K-12 ORF archive): unique resources for biological research.大肠杆菌ASKA文库的全套开放阅读框克隆（大肠杆菌K-12开放阅读框文库全集）：生物学研究的独特资源。
DNA Res. 2005;12(5):291-9. doi: 10.1093/dnares/dsi012. Epub 2006 Jan 9.
8
Binding sites of VanRB and sigma70 RNA polymerase in the vanB vancomycin resistance operon of Enterococcus faecium BM4524.屎肠球菌BM4524的vanB万古霉素抗性操纵子中VanRB与σ70 RNA聚合酶的结合位点。
Mol Microbiol. 2005 Jul;57(2):550-64. doi: 10.1111/j.1365-2958.2005.04706.x.
9
Efflux-mediated antimicrobial resistance.外排介导的抗菌药物耐药性。
J Antimicrob Chemother. 2005 Jul;56(1):20-51. doi: 10.1093/jac/dki171. Epub 2005 May 24.
10
In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance.磷霉素对革兰氏阴性尿路病原体的体外活性及磷霉素耐药的生物学代价。
Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:53-9. doi: 10.1016/s0924-8579(03)00230-9.

全基因组过表达筛选大肠杆菌对磷霉素的耐药性：MurA 以低适应性成本赋予临床耐药性。

Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost.

机构信息

Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain.

出版信息

Antimicrob Agents Chemother. 2012 May;56(5):2767-9. doi: 10.1128/AAC.06122-11. Epub 2012 Feb 27.

DOI:10.1128/AAC.06122-11
PMID:22371901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3346583/
Abstract

To determine whether the overexpression of chromosomal genes can confer fosfomycin resistance, genomewide screening of a complete set of 5,272 plasmid-expressed open reading frames of Escherichia coli (ASKA collection) was performed. Major results are that (i) no clinical level of resistance is achieved by overexpressing chromosomal genes, except murA; (ii) this level is reached at a low fitness cost; and (iii) this cost is much lower than that imposed by other mutations conferring fosfomycin resistance.

摘要

为了确定染色体基因的过表达是否可以赋予磷霉素抗性，对大肠杆菌的整套 5272 个质粒表达开放阅读框（ASKA 集合）进行了全基因组筛选。主要结果是：（i）除 murA 外，过表达染色体基因不能达到临床水平的抗性；（ii）这种水平是以低适应性成本达到的；（iii）这种成本比赋予磷霉素抗性的其他突变所施加的成本低得多。